Originally organized around antitumor technologies, including angiogenesis inhibition, VasGene had been a clinical-stage company dedicated to the development and commercialization of innovative therapeutics based on the understanding of vascular biology. Breakthroughs in the basic understanding of the vascular networks combined with powerful new biotechnological tools, provided the foundation for new, rational, and technologically sophisticated approaches to cancer therapeutics. VasGenes products target signal transduction pathways common to cancer cells and endothelial cells, resulting in powerful anti-cancer agents with multiple modes of action: inhibition of tumor cell growth, anti-angiogenesis, and prevention of tumor cell metastasis. VasGene had developed an extensive and well-protected intellectual property portfolio covering various therapeutic targets. Some time during 2018, the firm was posted as having been dissolved